Scholarlink

Background and aim <p>Olanzapine, a widely used second-generation antipsychotic, is associated with notable metabolic side effects, particularly dyslipidemia. However, the extent, timing, and dose-dependence of these lipid alterations remain inadequately defined. This meta-analysis aimed to quantify the effects of olanzapine on lipid profiles in humans and to evaluate how dosage and treatment duration influence these changes.</p> Methods <p>A systematic search of Scopus, Web of Science, Embase, and PubMed/MEDLINE was conducted to identify randomized controlled trials (RCTs) published up to December 1, 2025. Studies were eligible if they reported lipid outcomes (triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], and low-density lipoprotein cholesterol [LDL-C]) before and after olanzapine treatment. Pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup, dose-response, and sensitivity analyses were performed to explore sources of heterogeneity and assess result robustness.</p> Results <p>Seventeen trials were included. Olanzapine significantly increased TG (WMD: 24.96&#xa0;mg/dL), TC (WMD: 6.57&#xa0;mg/dL), and LDL-C (WMD: 4.30&#xa0;mg/dL), while HDL-C decreased non-significantly (WMD: − 1.33&#xa0;mg/dL). Subgroup analyses revealed that lipid alterations were more pronounced with higher doses (≥ 10&#xa0;mg/day), shorter treatment durations (&lt; 12 weeks), and in individuals with baseline body mass index (BMI) &lt; 25&#xa0;kg/m². Dose-response analysis showed a positive correlation between olanzapine dose and increases in TG and TC, and a negative correlation with HDL-C. Sensitivity analyses confirmed the robustness of findings, and no publication bias was detected for TG or HDL-C.</p> Conclusion <p>Olanzapine treatment is associated with a distinct dyslipidemic profile, characterized by increased TG, TC, and LDL-C and reduced HDL-C, particularly at higher doses and during early treatment. These findings underscore the need for proactive lipid monitoring and cardiovascular risk assessment, especially in patients with low baseline BMI, who appear more susceptible to rapid lipid alterations, and in those with existing metabolic risk factors or multiple cardiometabolic comorbidities.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effect of olanzapine on lipid profiles in humans: a time and dose response meta-analysis of randomized controlled trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月6日

查看全文
  • Zhou Fang,
  • Parmida Jamilian,
  • Mohammad Safargar,
  • Kousalya Prabahar,
  • Liu Shuang

摘要

Background and aim

Olanzapine, a widely used second-generation antipsychotic, is associated with notable metabolic side effects, particularly dyslipidemia. However, the extent, timing, and dose-dependence of these lipid alterations remain inadequately defined. This meta-analysis aimed to quantify the effects of olanzapine on lipid profiles in humans and to evaluate how dosage and treatment duration influence these changes.

Methods

A systematic search of Scopus, Web of Science, Embase, and PubMed/MEDLINE was conducted to identify randomized controlled trials (RCTs) published up to December 1, 2025. Studies were eligible if they reported lipid outcomes (triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL-C], and low-density lipoprotein cholesterol [LDL-C]) before and after olanzapine treatment. Pooled weighted mean differences (WMDs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup, dose-response, and sensitivity analyses were performed to explore sources of heterogeneity and assess result robustness.

Results

Seventeen trials were included. Olanzapine significantly increased TG (WMD: 24.96 mg/dL), TC (WMD: 6.57 mg/dL), and LDL-C (WMD: 4.30 mg/dL), while HDL-C decreased non-significantly (WMD: − 1.33 mg/dL). Subgroup analyses revealed that lipid alterations were more pronounced with higher doses (≥ 10 mg/day), shorter treatment durations (< 12 weeks), and in individuals with baseline body mass index (BMI) < 25 kg/m². Dose-response analysis showed a positive correlation between olanzapine dose and increases in TG and TC, and a negative correlation with HDL-C. Sensitivity analyses confirmed the robustness of findings, and no publication bias was detected for TG or HDL-C.

Conclusion

Olanzapine treatment is associated with a distinct dyslipidemic profile, characterized by increased TG, TC, and LDL-C and reduced HDL-C, particularly at higher doses and during early treatment. These findings underscore the need for proactive lipid monitoring and cardiovascular risk assessment, especially in patients with low baseline BMI, who appear more susceptible to rapid lipid alterations, and in those with existing metabolic risk factors or multiple cardiometabolic comorbidities.